JP2025520692A - 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用 - Google Patents

抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用 Download PDF

Info

Publication number
JP2025520692A
JP2025520692A JP2024575463A JP2024575463A JP2025520692A JP 2025520692 A JP2025520692 A JP 2025520692A JP 2024575463 A JP2024575463 A JP 2024575463A JP 2024575463 A JP2024575463 A JP 2024575463A JP 2025520692 A JP2025520692 A JP 2025520692A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024575463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025520692A5 (https=
Inventor
ルンシェン リー，
ウェンタオ ファン，
イーファン リー，
Original Assignee
ラノバ メディシンズ デベロップメント カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラノバ メディシンズ デベロップメント カンパニー， リミテッド filed Critical ラノバ メディシンズ デベロップメント カンパニー， リミテッド
Publication of JP2025520692A publication Critical patent/JP2025520692A/ja
Publication of JP2025520692A5 publication Critical patent/JP2025520692A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024575463A 2022-06-22 2023-06-21 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用 Pending JP2025520692A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/100315 2022-06-22
CN2022100315 2022-06-22
PCT/CN2023/101761 WO2023246879A1 (en) 2022-06-22 2023-06-21 Anti-slc34a2 monoclonal antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025520692A true JP2025520692A (ja) 2025-07-03
JP2025520692A5 JP2025520692A5 (https=) 2026-04-20

Family

ID=89379184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024575463A Pending JP2025520692A (ja) 2022-06-22 2023-06-21 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用

Country Status (13)

Country Link
US (2) US12215150B2 (https=)
EP (1) EP4543926A1 (https=)
JP (1) JP2025520692A (https=)
KR (1) KR20250051643A (https=)
CN (1) CN119948054A (https=)
AU (1) AU2023289743A1 (https=)
CA (1) CA3260354A1 (https=)
CL (1) CL2024004012A1 (https=)
CO (1) CO2024017740A2 (https=)
IL (1) IL317849A (https=)
MX (1) MX2025000053A (https=)
TW (1) TW202409076A (https=)
WO (1) WO2023246879A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025131025A1 (en) * 2023-12-21 2025-06-26 Lanova Medicines Development Co., Ltd. Conjugates of anti-slc34a2 antibody and uses thereof
CN120988123B (zh) * 2025-10-21 2026-03-17 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603474B2 (en) 2008-01-29 2013-12-10 Ludwig Institute For Cancer Research, Ltd. Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
US12215150B2 (en) 2025-02-04
EP4543926A1 (en) 2025-04-30
TW202409076A (zh) 2024-03-01
US20240301052A1 (en) 2024-09-12
AU2023289743A1 (en) 2025-01-09
CL2024004012A1 (es) 2025-05-02
CO2024017740A2 (es) 2025-05-19
US20250154248A1 (en) 2025-05-15
MX2025000053A (es) 2025-04-02
KR20250051643A (ko) 2025-04-17
CA3260354A1 (en) 2023-12-28
WO2023246879A1 (en) 2023-12-28
CN119948054A (zh) 2025-05-06
IL317849A (en) 2025-02-01

Similar Documents

Publication Publication Date Title
US11634490B2 (en) Blocking antibodies against CD47 and methods of use thereof
JP2025135612A (ja) 抗クローディン－１８．２と抗４－１ｂｂとの二重特異性抗体およびその使用
JP7672172B6 (ja) 抗ＳＩＲＰαモノクローナル抗体およびその使用
JP7565117B2 (ja) 抗ｔｉｇｉｔ抗体およびその使用
JP7595176B2 (ja) 抗ｇｐｒｃ５ｄモノクローナル抗体及びその用途
WO2022206961A1 (en) Anti-cd24 monoclonal antibodies and uses thereof
US20250154248A1 (en) Anti-slc34a2 monoclonal antibodies and uses thereof
WO2022148370A1 (en) Anti-gprc5d monoclonal antibodies and uses thereof
JP2025010203A (ja) Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子
WO2025131027A1 (en) Anti-slc34a2/anti-4-1bb antibodies and uses thereof
WO2023155796A1 (en) Anti-il-13ra2 monoclonal antibodies and uses thereof
TWI883306B (zh) 抗ｇｐｒｃ５ｄ單株抗體及其用途
HK40126806A (zh) 抗slc34a2单克隆抗体及其用途
HK40080157A (en) Anti-gprc5d monoclonal antibodies and uses thereof
HK40080157B (zh) 抗gprc5d单克隆抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260410